Idorsia (XSWX:IDIA) FFO


XSWX:IDIA Idorsia Ltd XSWX:IDIA
49 GF Score
Price CHF6.86
GF Value CHF2.85
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Idorsia FFO?

FFO (Funds from operations) only applies to REITs.

XSWX:IDIA
49GF Score
Idorsia Ltd XSWX:IDIA
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Idorsia (XSWX:IDIA) Overvalued in 2026?

Based on GuruFocus' analysis, Idorsia stock appears to be overvalued. The current stock price of CHF6.86 is trading 140.7% above its estimated GF Value™ of CHF2.85. GuruFocus considers Idorsia to be Significantly Overvalued.

Key valuation signals for XSWX:IDIA:

  • FFO:
  • GF Value™: CHF2.85 vs. price of CHF6.86 (140.7% above fair value)
  • GF Score™: 49/100 with 3 warning signs

No single metric tells the full story. See the XSWX:IDIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Idorsia Business Description

Address Hegenheimermattweg 91, Allschwil, CHE, 4123
Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. The company is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide new therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. The company's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.
49GF Score

Get the complete analysis for XSWX:IDIA

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF6.86
Price
CHF2.85
GF Value